Administering steroids with HIV treatment‐boosting agents

Abstract

Co‐administration of a steroid with an HIV treatment‐boosting agent such as ritonavir or cobicistat increases the risk of iatrogenic Cushing syndrome and subsequent secondary adrenal suppression. This article discusses the strategies to help prevent this and describes how to identify and manage such interactions.